WATCH: SpaceX Starship explodes during engine test
A SpaceX Starship spacecraft exploded overnight during a rocket engine test in Texas.
Video shows a massive fireball as the rocket ignited.
The company said the rocket 'experienced a major anomaly' while doing a rocket engine test fire.
It happened at SpaceX's Starbase launch site in southern Texas.
SpaceX says there was a safety zone around the area during the operation, and all personnel are safe.
Officials said there was no danger to nearby communities and asked people to stay away from the site.
This isn't the first issue for the SpaceX Starship rocket.
Two of the three most recent flights ended in explosions before the massive spacecraft could reach its planned flight path.
Click here to download our free news, weather and smart TV apps. And click here to stream Channel 9 Eyewitness News live.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
The American Diabetes Association Demonstrates Its Commitment to Curbing the Obesity Epidemic with Obesity Standards of Care
Symposium previews new content for Standards of Care in Overweight and Obesity, designed to improve patient care and outcomes CHICAGO, June 20, 2025 /PRNewswire/ -- Recent developments for the new Standards of Care in Overweight and Obesity guidelines, the first clinical guidance of its kind, were presented during the Standards of Care in Overweight and Obesity 2025 Updates symposium at the 85th Scientific Sessions of the American Diabetes Association® (ADA) in Chicago. The Obesity Association™, a division of the ADA, recently announced the publication of Weight Stigma and Bias: Standards of Care in Overweight and Obesity—2025, along with the Introduction & Methodology section in BMJ Open Diabetes Research & Care. This comes at a time when about 110 million American adults are impacted by obesity. Further, up to (53%) of new cases of type 2 diabetes are attributed to obesity every year, demonstrating the need for comprehensive, evidence-based guidelines to inform care. The symposium highlighted key insights on physician guidelines for weight stigma and bias, including training for health care professionals, creating inclusive clinical environments, person-centered communication, shared decision making, and evidence-based interventions. Additionally, researchers highlighted what is next for the clinical guidelines, including a potential section for pharmacologic treatment and a preview of what is going to be covered in that section. The Standards of Care in Overweight and Obesity 2025 Updates symposium is one of many obesity-related symposia and abstracts at the 85th Scientific Sessions, spanning basic through clinical and implementation science. Additional studies highlighting groundbreaking developments obesity treatment and care to be presented at ADA's annual meeting include: Once-Monthly MariTide for the Treatment of Obesity in People with or without Type 2 Diabetes—A 52-Week Phase 2 Study ADJUnct Semaglutide Treatment in Type 1 Diabetes (ADJUST-T1D) Trial Outcomes Can We Improve the Quality of Weight Loss by Augmenting Fat Mass Loss while Preserving Lean Mass? The BELIEVE Study of Bimagrumab + Semaglutide PATHWEIGH Trial—Building the Highway for Weight Management in Primary Care First Report of a Phase 3 RCT of Orforglipron, a Small Nonpeptide GLP-1RA, as Monotherapy in Drug-Naïve Type 2 Diabetes with Inadequate Glycemic Control—The ACHIEVE-1 Trial Efficacy and Safety of CagriSema 2.4mg/2.4mg in Adults with Overweight/Obesity—The REDEFINE 1 and REDEFINE 2 Clinical Trials "The ADA's Standards of Care in Diabetes guideline is the gold standard for diabetes care and management," said Raveendhara Bannuru, MD, PhD, the ADA's vice president, medical affairs and lead author of the guidelines. "The new Standards of Care in Overweight and Obesity guidelines stand to yield significant impact and progress in patient care, and it's only just the beginning." As part of the ADA's ongoing commitment to combating obesity, new clinical practice guidelines and initiatives are continually being developed to advance the quality of care. Research presentation details:Dr. Bannuru and other Professional Practice Committee members will present these findings at the symposium: Standards of Care in Overweight and Obesity 2025 Updates Friday, June 20 from 12:45–1:45 p.m. About the ADA's Scientific SessionsThe ADA's 85th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in Chicago, IL, on June 20–23. Thousands of leading physicians, scientists, and health care professionals from around the world are expected to convene both in person and virtually to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. Attendees will receive exclusive access to thousands of original research presentations and take part in provocative and engaging exchanges with leading diabetes experts. Join the Scientific Sessions conversation on social media using #ADASciSessions. About the Obesity Association Obesity is an epidemic that demands both attention and action. The Obesity Association, a division of the American Diabetes Association, is dedicated to reducing the prevalence of obesity and improving health outcomes. Through a focus on education, action, and evidence-based support, we strive to create a world where people affected by obesity can thrive. About the American Diabetes AssociationThe American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to end diabetes and helping people thrive. This year, the ADA celebrates 85 years of driving discovery and research to prevent, manage, treat, and ultimately cure—and we're not stopping. There are 136 million Americans living with diabetes or prediabetes. Through advocacy, program development, and education, we're fighting for them all. To learn more or to get involved, visit us at or call 1-800-DIABETES (800-342-2383). Join us in the fight on Facebook (American Diabetes Association), Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn (American Diabetes Association), and Instagram (@AmDiabetesAssn). To learn more about how we are advocating for everyone affected by diabetes, visit us on X (@AmDiabetesAssn). Media Contact: Mimi Carmody, MCarmody@ View original content to download multimedia: SOURCE American Diabetes Association Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
L-Nutra Health Unveils Real-World Diabetes Remission Outcomes at ADA, Spotlighting Success of Nutrition-Driven Lifestyle Medicine
Results highlight A1C improvements, reduced reliance on medications, and strong patient engagement through personalized, root-cause-based care CHICAGO, June 20, 2025 /PRNewswire/ -- L-Nutra Health, the medical division of nutrition technology leader L-Nutra, presented compelling real-world data today at the American Diabetes Association's 85th Scientific Sessions, reinforcing the success of lifestyle medicine in reversing the course of type 2 diabetes. The data reflects the outcomes of a comprehensive, clinically guided nutrition and lifestyle program that supports the management and potential reversal of metabolic disease and type 2 diabetes at their root—addressing insulin resistance, visceral fat, and cellular aging. The outcomes, drawn from 125 individuals enrolled in L-Nutra Health's Diabetes Remission and Regression Program (DRRP), demonstrated improvements in glycemic control, reductions in diabetes medication use, and meaningful weight loss—without relying on pharmaceutical or lifestyle intensification. "This is a powerful demonstration of what happens when you replace reactive care with proactive, personalized nutrition therapy," said Dr. Joseph Antoun, MD, CEO and Chairman of L-Nutra. "Instead of managing symptoms, we're helping patients resolve the underlying dysfunction driving their disease." Key outcomes presented: The mean age of the study volunteers was 61.7 years, with body mass index of 31.8, diabetes duration of 10.7 years and baseline HbA1c of 7.6%. 54% of participants reduced diabetes medications at 3 months; 68% at 6 months HbA1c decreased by 0.5 % at 3 months and maintained at 6 months Average weight loss of 4.0 kg at 3 months and 5.1 kg at 6 months Diabetes Treatment Satisfaction Score (DTSQ) improved from 26.9 at baseline to 30.4 at 6 months The abstract was presented by Ashley Bizzell RD, LDN, CDCES, Director of Clinical Nutrition and Global Training at L-Nutra Health, who leads the clinical nutrition team delivering the intervention. "These findings are truly encouraging—pairing the fasting-mimicking diet with personalized guidance and support from a dietitian presents a compelling approach to driving remission in type 2 diabetes," said Bizzell. "As a dietitian, it reinforces the critical role that nutrition-centered care can play in reversing chronic disease and restoring metabolic health." "The Fasting Mimicking Diet (FMD) is a patented, nutrition-based therapeutic that delivers the cellular and metabolic benefits of fasting—without full food deprivation," said Dr. William Hsu, MD, Chief Medical Officer of L-Nutra and former VP at Harvard's Joslin Diabetes Center. "When integrated with physician oversight and registered dietitian support, it enables clinically significant metabolic improvements with less dependence on costly medications and minimal lifestyle disruption—an outcome rarely achieved in standard care." An Innovative Model Based on Personalized, Root-Cause CareThe L-Nutra Health program integrates evidence-based nutrition protocols—including a patented, low-glycemic dietary intervention that mimics the effects of fasting—with bi-monthly Registered Dietitian coaching, medical oversight by a team of board-certified lifestyle medicine physicians, laboratory review, and medication reduction as appropriate. Patients receive individualized care plans that aim to drive disease remission and regression, optimize weight care, improve insulin sensitivity and biological age score —shifting the treatment paradigm from glucose control to true metabolic restoration. Backed by over 25 years of research, including funding from the NIH and clinical partnerships with 34 global institutions, this model offers a cost-effective, sustainable, and scalable alternative to pharmaceutical-first diabetes care. To learn more about L-Nutra Health's Diabetes Remission & Regression Program, visit About L-Nutra HealthL-Nutra Health is transforming how metabolic disease is treated—through lifestyle medicine-based therapeutic programs that address root causes, drive towards disease remission, and reduce medication reliance. Founded on the scientific discoveries of Dr. Valter Longo and backed by over $36 million in NIH funding, L-Nutra Health integrates nutri-technology , digital tools, and expert care to create structured, personalized programs for diabetes, obesity, insulin resistance, hypertension and more. View original content to download multimedia: SOURCE L-Nutra Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
2 hours ago
- Forbes
Is ChatGPT Making Us Stupid?
Two research studies suggest that heavy use of AI is not only a game changer, but an alarming threat ... More to humanity's ability to solve problems, communicate with one another, and perhaps to thrive. In boardrooms and classrooms, coffee shops and cubicles, the same question keeps coming up: Is ChatGPT making us smarter, or is it making us intellectually lazy—maybe even stupid? There's no question that generative artificial intelligence is a game-changer. ChatGPT drafts our emails, answers our questions, and completes our sentences. For students, it's become the new CliffsNotes. For professionals, a brainstorming device. For coders, a potential job killer. In record time, it has become a productivity enhancer for almost everything. But what is it doing to our brains? As someone who has spent his career helping clients anticipate and prepare for the future, this question deserves our attention. With any new technology, concerns inevitably arise about its impact. When calculators were first introduced, people worried that students would lose their ability to perform basic arithmetic or mental math skills. When GPS was first introduced, some fretted that we would lose our innate sense of direction. And when the internet bloomed, people grew alarmed that easy access to information would erode our capacity for concentration and contemplation. 'Our ability to interpret text, to make the rich mental connections that form when we read deeply and without distraction, is what often gets shortchanged by internet grazing,' noted technology writer Nicholas Carr in a prescient 2008 Atlantic article, 'Is Google Making Us Stupid?' Today, Carr's question needs to be asked anew – but of a different techno-innovation. Just-released research studies are helping us understand what's going on when we allow ChatGPT to think for us. What Happens to the Brain on ChatGPT? Researchers at MIT invited fifty-four participants to write essays across four sessions, divided into three groups: one using ChatGPT, one using Google, and one using only their brainpower. In the final session, the groups switched roles. What these researchers found should make all of us pause. Participants who used ChatGPT consistently produced essays that scored lower in originality and depth than those who used search or wrote unaided. More strikingly, brain imaging revealed a decline in cognitive engagement in ChatGPT users. Brain regions associated with attention, memory, and higher-order reasoning were noticeably less active. The MIT researchers introduced the concept of "cognitive debt"—the subtle but accumulating cost to our mental faculties when we outsource too much of our thinking to AI. 'Just as relying on a GPS dulls our sense of direction, relying on AI to write and reason can dull our ability to do those very things ourselves,' notes the MIT report. 'That's a debt that compounds over time.' The second study, published in the peer-reviewed Swiss journal Societies, is titled 'AI Tools in Society: Impacts on Cognitive Offloading and the Future of Critical Thinking.' It broadens the lens from a lab experiment to everyday life. Researchers surveyed 666 individuals from various age and educational backgrounds to explore how often people rely on AI tools—and how that reliance affects their ability to think critically. The findings revealed a strong negative correlation between frequent AI use and critical thinking performance. Those who often turned to AI for tasks like writing, researching, or decision-making exhibited lower 'metacognitive' awareness and analytical reasoning. This wasn't limited to any one demographic, but younger users and those with lower educational attainment were particularly affected. What's more, the study confirmed that over-reliance on AI encourages 'cognitive offloading'—our tendency to let external tools do the work our brains used to do. While cognitive offloading isn't new (we've done it for centuries with calculators and calendars), AI takes it to a whole new level. 'When your assistant can 'think' for you, you may stop thinking altogether,' the report notes. Are We Letting the Tool Use Us? These studies aren't anti-AI. Neither am I. I use ChatGPT daily. As a futurist, I see ChatGPT and similar tools as transformational breakthroughs—the printing press of the 21st century. They unlock productivity, unleash creativity, and lower barriers to knowledge. But just as the printing press didn't eliminate the need to learn to read, ChatGPT doesn't absolve us of the responsibility to think. And that is the danger today, that people will stop doing their own thinking. These studies are preliminary, and further research is needed. However, there is sufficient evidence to suggest that heavy use of AI is not only a game changer, but an alarming threat to humanity's ability to solve problems, communicate with one another, and perhaps to thrive. In integrating metacognitive strategies—thinking about thinking—into education, workplace training, and even product design. In other words, don't just use AI—engage with it. The line we must straddle is between augmentation and abdication. Are we using AI to elevate our thinking? Or are we turning over the keys to robots? Here are four ideas for using this new technology, while keeping our cognitive edge sharp: The danger isn't that ChatGPT will replace us. But it can make us stupid—if we let it replace our thinking instead of enriching it. The difference lies in how we use it, and more importantly, how aware we are while using it. The danger is that we'll stop developing the parts of ourselves that matter most—because it's faster and easier to let the machine do it. Let's not allow that to happen.
